Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy
Recombinant adeno-associated virus (AAV) vectors have been, or are currently in use, in 332 phase I/II/III clinical trials in a number of human diseases, and in some cases, remarkable clinical efficacy has also been achieved. There are now three US Food and Drug Administration (FDA)-approved AAV &qu...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Livro |
| Publicado em: |
Elsevier,
2023-06-01T00:00:00Z.
|
| Assuntos: | |
| Acesso em linha: | Connect to this object online. |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|